Patients with sickle cell disease have intermittent painful crises caused by occlusion of the microcirculation with sickled cells. Crises vary considerably in severity, ranging from mild episodes that respond at home to simple analgesics and oral rehydration, to extensive tissue infarction requiring parenteral opiates and intravenous fluids in hospital. In some episodes it is difficult to confirm that tissue infarction has occurred, and in others, to establish the time of onset as 58% of patients experience a prodromal phase for several hours, and sometimes days, beforehand.' During established crisis, pain may shift from site to site, the resolution of crisis may be protracted, and there may be complicating infection. Objective criteria to monitor the progress of crisis, guide the duration of treatment, and mark the end of crisis are required.
Quantitative measurement of the blood concentration of acute phase proteins is a valuable indicator of the onset, extent, and response to treatment of the inflammatory response to tissue damage. Such measurements may be of value for determining the onset of vaso-occlusive crisis2 and for detecting subclinical episodes of tissue ischaemia that occur in the asymptomatic steady state between crises.34
We therefore studied the prodromal and established phases of a total of 14 vasoocclusive crises in 10 patients to determine the value of new sensitive immunoassays for the fast responding proteins C-reactive protein and serum amyloid A protein (SAA) which show an increase in blood concentration within six to 10 hours of tissue injury. '6 To investigate longer term changes, we studied the individual slow responding glycoproteins fibrinogen and orosomucoid (al-acid glycoprotein), which show an increase within 24-48 hours of tissue injury.6 We also studied plasma sialic acid and concanavalin-A binding (con-A) as a measure of multiple slow responding glycoproteins.
Methods
Ten patients with severe sickle cell anaemia were studied longitudinally both when asymptomatic during the steady state and during a total of 14 painful crises. Eight crises were treated by the patient at home, using oral analgesics and fluids, with a research nurse visiting the patient to collect blood samples. In six crises the patient was admitted to hospital under the care of a consultant haematologist and serial blood samples were again collected, initially in hospital and then at home. All patients had been trained to keep a diary of symptoms during the steady state and to telephone whenever they had a premonition of sickle crisis.2 A home visit was then made to collect the first blood sample (day 1) in this prodromal phase of crisis.
SAA was measured using an automated monoclonal-polyclonal solid phase sandwich enzyme immunoassay run on the Abbott IM. The calibrators and controls were prepared from a stabilised denatured SAA concentrate. The assay has a potential sensitivity of 0-2 mg/l but, because it is less reproducible in this range, values below 1 mg/l are reported here as <1 mg/l. The upper limit is 300 mg/l and inter-and intra-assay coefficients of variation are 3-9-7 0% across the assay range. Samples containing SAA at concentrations above the upper assay limit were rerun at higher dilutions. Among 100 healthy normal subjects, the mean (SD) SAA concentration was 3-7 (3 6) mg/l and the median (range) was 3 0 (0 7- 26 4) The assay has a sensitivity of 0-05 mg/l, upper limit of 30 mg/l, and inter-and intra-assay coefficients of variation of <10-0% across the assay range. Samples containing C-reactive protein at concentrations above the upper assay limit were rerun at higher dilutions. The median normal value is 0-8 mg/l; 90% of healthy subjects have concentrations below 3 mg/l and 99% are below 10 mg/1. 8 Plasma fibrinogen and serum orosomucoid were measured using radial immunodiffusion kits (The Binding Site Ltd, Birmingham). Sialic acid was measured on citrated plasma, using an enzyme assay test kit (Kyokuto Pharmaceutical Industrial Co Ltd, Tokyo) based on the method of Sugahara et al,9 and expressed as percentage activity relative to the manufacturer's lyophilised control serum, with correction for dilution by the liquid anticoagulant. Con-A was measured on citrated plasma by laser nephelometry based on the method of Warren et al 10 and expressed similarly.
Significance was determined by the nonparametric Wilcoxon matched pairs signed ranking test. The fast responding acute phase proteins C-reactive protein and SAA were also studied in the above (plus four additional) crises in the same 10 patients. Of six crises treated in hospital (table 2), three crises resolved within 24 hours; two of these patients were then discharged but the third developed a vitreous haemorrhage in the left eye and remained in hospital for a total of 11 days. The remaining three crises required hospital treatment for four, five, and 10 days. Case 1 had a urinary tract infection and case 4 (crisis 2) became febrile on day 2 and developed x ray evidence of chest infection. There was no apparent infection in association with the other crises, whether treated in hospital or at home.
Patients with crises that resolved within 24 hours in hospital (table 2) demonstrated a minor acute phase rise in C-reactive protein and SAA compared with the greater rise in patients admitted for four days or more. Patients who treated their crises at home (table 3) showed a varying degree of acute phase response, ranging from a minimal rise in C-reactive protein and SAA, to concentrations that matched those observed in patients admitted to hospital for four days or more. Whether treated in hospital or at home, the day 1 specimens reflected the earliest identifiable stage of crisis (prodromal phase) and the increase in blood concentration within six to 10 hours of tissue injury so that our day 1 values probably did reflect an early stage of the evolution of vaso-occlusion.5 6 This study shows a wide range in clinical severity and inflammatory response to tissue ischaemia of sickle cell crisis, including those episodes of pain that patients elect to treat at home. Objective markers of the evolution of this process are therefore required, particularly during the early (prodromal) stage of crisis when therapeutic intervention is more likely to be effective. A fast responding and sensitive marker of tissue ischaemia also allows resolution of crisis to be monitored, so that treatment can be regulated accordingly. These new immunoassays for C-reactive protein and SAA are identified as candidate markers that now require evaluation in a larger cohort of patients studied longitudinally. The acute phase response to tissue injury is known to be non-specific, however, and does not differentiate between infarction and infection either in sickle cell disease or in other disorders.18 Resolution of infection that accompanies sickle cell crisis can also be monitored using C-reactive protein and SAA, concentrations of which can fall with a halftime as fast as 24 hours following complete resolution of the provoking stimulus. '9 
